Evidence map›Paper›PMID 41696631›Full record

ArticleMolecular therapy. Oncology2026

Suppression of PARP1 enhances PTEN mRNA therapy in castration-resistant prostate cancer by glycolysis disruption.

Bo Hu, Pengfei Wu, Lulu Zheng, Haiyin Yang, Yuchuan Fan, Jun Yang, Lu Tang, Sudong Kong, Chao Zhu, Minghui Yang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Bo HuSchool of Interdisciplinary Science, School of Medical Engineering, Affiliated Zhuhai People's Hospital, Frontier Interdisciplinary Domain, Beijing Institute of Technology, Zhuhai 519088, P.R. China.
Pengfei WuSchool of Life Science, School of Interdisciplinary Science, Key Laboratory of Molecular Medicine and Biotherapy, Key Laboratory of Medical Molecule Science and Pharmaceutics Engineering, Beijing Institute of Technology, Beijing 100081, P.R. China.
Lulu ZhengSchool of Life Science, School of Interdisciplinary Science, Key Laboratory of Molecular Medicine and Biotherapy, Key Laboratory of Medical Molecule Science and Pharmaceutics Engineering, Beijing Institute of Technology, Beijing 100081, P.R. China.
Haiyin YangSchool of Life Science, School of Interdisciplinary Science, Key Laboratory of Molecular Medicine and Biotherapy, Key Laboratory of Medical Molecule Science and Pharmaceutics Engineering, Beijing Institute of Technology, Beijing 100081, P.R. China.
Yuchuan FanSchool of Life Science, School of Interdisciplinary Science, Key Laboratory of Molecular Medicine and Biotherapy, Key Laboratory of Medical Molecule Science and Pharmaceutics Engineering, Beijing Institute of Technology, Beijing 100081, P.R. China.
Jun YangSchool of Life Science, School of Interdisciplinary Science, Key Laboratory of Molecular Medicine and Biotherapy, Key Laboratory of Medical Molecule Science and Pharmaceutics Engineering, Beijing Institute of Technology, Beijing 100081, P.R. China.
Lu TangInstitute for Experimental Molecular Imaging, Uniklinik RWTH Aachen and Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, 52074 Aachen, Germany.
Sudong KongSuzhou Biosyntech Co., Ltd., Suzhou 215300, P.R. China.
Chao ZhuInstitute of Quality Standard and Testing Technology for Agro-products, Shandong Academy of Agricultural Sciences, Ji'nan 250100, P.R. China.
Minghui YangSchool of Interdisciplinary Science, School of Medical Engineering, Affiliated Zhuhai People's Hospital, Frontier Interdisciplinary Domain, Beijing Institute of Technology, Zhuhai 519088, P.R. China.
Jiatao ZhangSchool of Interdisciplinary Science, School of Medical Engineering, Affiliated Zhuhai People's Hospital, Frontier Interdisciplinary Domain, Beijing Institute of Technology, Zhuhai 519088, P.R. China.
Qing LiuSchool of Life Science, School of Interdisciplinary Science, Key Laboratory of Molecular Medicine and Biotherapy, Key Laboratory of Medical Molecule Science and Pharmaceutics Engineering, Beijing Institute of Technology, Beijing 100081, P.R. China.
Yuanyu HuangSchool of Interdisciplinary Science, School of Medical Engineering, Affiliated Zhuhai People's Hospital, Frontier Interdisciplinary Domain, Beijing Institute of Technology, Zhuhai 519088, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Current treatments for prostate cancer (PC) inevitably lead to the development of resistance to androgen deprivation therapy, resulting in the emergence of castration-resistant prostate cancer (CRPC), which is currently considered incurable. In this study, we discovered that the loss of phosphatase and tensin homolog (PTEN) function, in combination with elevated poly(ADP-ribose) polymerase 1 (PARP1) expression, significantly shortens the survival of PC patients. Motivated by this finding, we developed an RNA-based therapeutic agent consisting of PARP1-targeting small interfering RNA (siRNA) (siPARP1) and PTEN-expressing mRNA (mPTEN), which were co-encapsulated in an ionizable lipid nanoparticle, named mPsiP@miLAND. Both siPARP1 and mPTEN were shown to individually attenuate tumor cell growth. Moreover, the simultaneous regulation of these two targets nearly completely suppressed proliferation and robustly induced apoptosis and necrosis in CRPC both

Indexed as

castration-resistant prostate cancerlipid nanoparticlemRNAMT: Regular IssuePARP1PTENsiRNA

Identifiers

PMID41696631
PMCPMC12905993

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.